Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05728879 · ClinicalTrials.gov registry record · Early Phase 1
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
A Early Phase 1 study, sponsored by Northwestern University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
NCT05728879 is a Early Phase 1 study that has not yet begun recruiting, run by Northwestern University. The registered enrollment target is 30 participants.
The verdict
NCT05728879, a Early Phase 1 study, has not yet begun recruiting, sponsored by Northwestern University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This open-label, pilot study will evaluate the tolerance and change in the microbiome from the use of APR-TD011 ((RLF-TD011) wound cleansing spray for the treatment of CTCL skin lesions.
Interventions
- COMBINATION_PRODUCT APR-TD011 (RLF-TD011)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2027-01 |
| Est. Completion | 2028-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05728879
The ClinicalTrials.gov registry entry for NCT05728879 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which APR-TD011 (RLF-TD011) is the first listed.
NCT05728879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05728879 about?
NCT05728879 is a clinical study titled "Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution". This open-label, pilot study will evaluate the tolerance and change in the microbiome from the use of APR-TD011 ((RLF-TD011) wound cleansing spray for the treatment of CTCL skin lesions.
What is the current status of trial NCT05728879?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2027-01. Estimated completion is 2028-12.
What interventions are being tested in trial NCT05728879?
The interventions under investigation include: APR-TD011 (RLF-TD011) (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05728879?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.